Skip to main content
SpringerLink
Log in

Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Objective: To assess the responsiveness of the EuroQol (EQ-5D) by comparing it with the Functional Living Index-Cancer (FLIC) and a self-reported rating of health-related quality of life (HRQL). Methods: HRQL was measured four times during the course of high dose chemotherapy (HDC) and bone marrow transplantation in 40 patients with stage II and III breast cancer. Measurements were at baseline (T1), pre-HDC (T2), 3 weeks post-HDC (T3), and 3 months post-HDC (T4). Results: Effect size ranged from 1.16 (T1–T3) to 0.66 (T3–T4) for the EQ-5D and 0.85–0.91 respectively for the FLIC. No significant differences in effect sizes between the EQ-5D and the FLIC were found. Repeated measures ANOVA yielded a significant change for all measures, with HRQL decreasing post-HDC and returning to baseline levels by 3 m post-HDC. EQ-5D dimensions changed significantly over time for mobility, self-care, and usual activities. EQ-5D index scores at T3 had a bimodal distribution. Interpretation of psychological changes was facilitated by an analysis of FLIC items. Conclusions: The EQ-5D is responsive to the clinically large changes associated with HDC in breast cancer patients. The bimodal distribution of the EQ-5D index has implications for the interpretation of EQ-5D change scores.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brooks R. EuroQol: The current state of play. Health Policy 1996; 37(1): 53–72.

    Article  PubMed  CAS  Google Scholar 

  2. Goodyear MDE, Fraumeni MA. Incorporating quality of life assessment into clinical cancer trials. In: Spilker B (ed), Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn., Philadelphia: Lippincott-Raven, 1996; 1003–1013.

    Google Scholar 

  3. Norum J, Angelsen V, Wist E, Olsen JA. Treatment costs in Hodgkin's disease: A cost-utility analysis. Eur J Cancer 1996; 32A(9): 1510–1517.

    Article  PubMed  CAS  Google Scholar 

  4. Uyl-de Groot CA, Vellenga E, de Vries EGE, Lowenberg B, Stoter GJ, Rutten FFH. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia: Results of a randomised placebo-controlled trial. Pharmacoeconomics 1997; 12(3): 351–360.

    Article  PubMed  CAS  Google Scholar 

  5. Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996; 14(2): 619–627.

    PubMed  CAS  Google Scholar 

  6. Cronbach LJ, Meehl PE. Construct validity in psychological tests. Psychol Bull 1955; 52: 281–302.

    Article  PubMed  CAS  Google Scholar 

  7. Hays RD, Hadorn D. Responsiveness to change: An aspect of validity, not a separate dimension. Qual Life Res 1992; 1(1): 73–75.

    Article  PubMed  CAS  Google Scholar 

  8. Messick S. Validity. In: Linn R (ed), Educational Measurement, 3rd edn., New York: Macmillan Publishing Company, 1989: 13–103.

    Google Scholar 

  9. Hollingworth W, Mackenzie R, Todd CJ, Dixon AK. Measuring changes in quality of life following magnetic resonance imaging of the knee: SF-36, EuroQol or Rosser index? Qual Life Res 1995; 4(4): 325–334.

    Article  PubMed  CAS  Google Scholar 

  10. Jenkinson C, Stradling J, Petersen S. How should we evaluate health status? A comparison of three methods in patients presenting with obstructive sleep apnoea. Qual Life Res 1998; 7(2): 95–100.

    Article  PubMed  CAS  Google Scholar 

  11. Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999; 8(1–2): 45–54.

    Article  PubMed  CAS  Google Scholar 

  12. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Item responsiveness of a rhinitis and asthma symptom score during a pollen season. J Asthma 1999; 36(5): 459–465.

    PubMed  CAS  Google Scholar 

  13. Jenkinson C, Gray A, Doll H, Lawrence K, Keoghane S, Layte R. Evaluation of index and profile measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36–Item Short Form Health Survey, EuroQol, and disease specific measures. Med Care 1997; 35(11): 1109–1118.

    Article  PubMed  CAS  Google Scholar 

  14. Brazier JE, Harper R, Munro J, Walters SJ, Snaith ML. Generic and condition-specific outcome measures for people with osteoarthritis of the knee. Rheumatology 1999; 38: 870–877.

    Article  PubMed  CAS  Google Scholar 

  15. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: Validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36(5): 551–559.

    Article  PubMed  CAS  Google Scholar 

  16. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11(6): 1132–1143.

    PubMed  CAS  Google Scholar 

  17. Seidman AD, Portenoy R, Yao TJ, et al. Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J National Cancer Instit 1995; 87(17): 1316–1322.

    CAS  Google Scholar 

  18. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998; 16(2): 501–514.

    PubMed  CAS  Google Scholar 

  19. Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998; 16(4): 1380–1387.

    PubMed  CAS  Google Scholar 

  20. Schipper H, Clinch JJ, McMurray A, Levitt M. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. J Clin Oncol 1984; 2(5): 472–483.

    PubMed  CAS  Google Scholar 

  21. Andrykowski MA, Bruehl S, Brady MJ, Henslee-Downey PJ. Physical and psychosocial status of adults one-year after bone marrow transplantation: A prospective study. Bone Marrow Transplant 1995; 15: 837–844.

    PubMed  CAS  Google Scholar 

  22. Clinch JJ. The Functional Living Index-Cancer: Ten years later. In: Spilker B (ed), Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed., Philadelphia: Lippincott-Raven, 1996; 215–225.

    Google Scholar 

  23. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11): 1095–1108.

    Article  PubMed  CAS  Google Scholar 

  24. Kornblith AB, Thaler HT, Wong G, et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995; 59(2): 231–242.

    Article  PubMed  CAS  Google Scholar 

  25. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997; 15(3): 974–986.

    PubMed  CAS  Google Scholar 

  26. Schag CA, Ganz PA, Heinrich RL. Cancer rehabilitation evaluation system — short form (CARES-SF). A cancer specific rehabilitation and quality of life instrument. Cancer 1991; 68(6): 1406–1413.

    Article  PubMed  CAS  Google Scholar 

  27. Glass GV, Hopkins KD. Statistical methods in education and psychology. 3rd edn., Needham Heights, MA: Allyn and Bacon, 1996.

    Google Scholar 

  28. Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993; 2: 441–449.

    Article  PubMed  CAS  Google Scholar 

  29. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, CA: Academic Press, Inc., 1985.

    Google Scholar 

  30. Curran D, Bacchi M, Hsu Schmitz SF, Molenberghs G, Sylvester RJ. Identifying the types of missingness in quality of life data from clinical trials. Statist Med 1998; 17: 739–756.

    Article  CAS  Google Scholar 

  31. Bernhard J, Hurny CDT, Coates A, Gelber RD. Applying quality of life principles in international cancer clinical trials. In: Spilker B (ed), Quality of life and pharmacoeconomics in clinical trials, 2nd edn., Philadelphia, Lippincotrt-Raven 1996; 693–705.

    Google Scholar 

  32. Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn., Hillsdale, New Jersey: Lawrence Erlbaum Associates, 1988.

    Google Scholar 

  33. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Int Med 1993; 118(8): 622–629.

    PubMed  CAS  Google Scholar 

  34. McQuellon RP, Craven B, Russell GB, et al. Quality of life in breast cancer patients before and after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 579–584.

    PubMed  CAS  Google Scholar 

  35. McQuellon RP, Russell GB, Rambo TD, et al. Quality of life and psychological distress of bone marrow transplant recipients: The ‘time trajectory’ to recovery over the first year. Bone Marrow Transplant 1998; 21: 477–486.

    Article  PubMed  CAS  Google Scholar 

  36. Breetvelt IS, Van Dam FSAM. Underreporting by cancer patients: The case of response-shift. Soc Sci Med 1991; 32(9): 981–987.

    Article  PubMed  CAS  Google Scholar 

  37. Conner-Spady B, Voaklander D, Suarez-Almazor M. Responsiveness of the EQ-5D compared with the WOMAC and SF-36 in patients with hip and knee replacements. In: Badia X, Herdman M, Roset M (eds), EuroQol Plenary Meeting, Sitges, Spain: Institut de Salut Pública de Catalunya 1999; 113–133.

    Google Scholar 

  38. Weijnen TJ, de Wit GA, de Charro F. An assessment of the applications of the EQ-5D in three fields in The Netherlands. In: Greiner W, Graf V.D. Schulenburg J-M, Piercy J (eds), EuroQol Plenary Meeting, Hannover: Uni-Verlag Witte 1998; 187–193.

    Google Scholar 

  39. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997; 36(7): 786–793.

    Article  PubMed  CAS  Google Scholar 

  40. Cronbach LJ, Furby L. How we should measure ‘change’ — or should we? Psychol Bull 1970; 74(1): 68–80.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Alberta, Edmonton, USA

    Barbara Conner-Spady & Philip Jacobs

  2. Cross Cancer Institute, Edmonton, USA

    Ceinwen Cumming

  3. University of California Los Angeles (UCLA), California, USA

    Jean-Marc Nabholtz

  4. Tom Baker Cancer Centre, Calgary, Canada

    Douglas Stewart

Authors
  1. Barbara Conner-Spady
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ceinwen Cumming
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Marc Nabholtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philip Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Douglas Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Conner-Spady, B., Cumming, C., Nabholtz, JM. et al. Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res 10, 479–486 (2001). https://doi.org/10.1023/A:1013018218360

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013018218360

Search

Navigation